대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Circulating Osteoglycin Predicts All-Cause Mortality and Major Cardiovascular Events in Patients with Advanced Chronic Kidney Disease: A Retrospective Analysis of a Randomized Controlled Study
저자	Seon ha BAEK1, Ran-hui CHA2, Shin wook KANG3, Cheol whee PARK4, Dae ryong CHA5, Sung gyun KIM6, Sun ae YOON7, Sejoong KIM8, Sang-youb HAN9, Jung hwan PARK10, Jae hyun CHANG11, Chun soo LIM12, Yon su KIM12, *Ki young NA8
출판정보	2017; 2017(1):
키워드	chronic kidney disease, osteoglycin, clinical outcomes
초록	Objectives : Patients with chronic kidney disease (CKD) have markedly increased rates of major adverse cardiovascular and cerebrovascular events (MACCEs) and mortality. Therefore, identifying early biomarkers predicting clinical outcomes in patients with CKD is critical. We aimed to determine whether osteoglycin (OGN) was associated with MACCEs or all-cause mortality, using data from a prospective randomized controlled study, K-STAR (Kremezin STudy Against Renal disease progression in Korea: NCT 00860431). Methods : A total of 383 patients (mean age: 56.4 years, men/women = 252/131) with CKD stage 3 to 4 from the original trial were enrolled in the present study. We measured serum OGN level and examined the impact of OGN on clinical outcomes. Results : The mean value of serum OGN levels was 13.0 ± 9.5 ng/mL. In multivariable analysis, lower proteinuria and hemoglobin; and higher levels of C-reactive protein were significantly associated with higher OGN levels. During a mean follow-up period of 56 months, 25 deaths, 61 MACCEs, and 75 composite outcomes occurred. In the nondiabetic group, serum OGN was significantly associated with all-cause mortality and composite outcome (hazard ratio [HR] = 1.058, P = 0.031; HR = 1.041, P = 0.036). However, serum OGN level was not associated with mortality, MACCEs, or composite outcome in the diabetic group. Conclusions : Our results indicated that serum OGN might be a predictor of adverse outcomes in patients with CKD, especially in nondiabetic patients with CKD, but not in diabetic patients with CKD.
원문(PDF)	PDF 원문보기

목록

위로가기